Fisher & Paykel Healthcare (ASX:FPH) update revenue and earnings on strong sales - Sequoia Direct Pty Ltd

21FebFebruary 21, 2020

Fisher & Paykel Healthcare (ASX:FPH) update revenue and earnings on strong sales

Fisher & Paykel Healthcare (ASX:FPH) has updated their revenue and earnings guidance on stronger Hospital and Homecare sales.

The New Zealand company, whose products include face and nasal masks for treating obstructive sleep apnea, said it expects full-year net profit of 260 million New Zealand dollars to NZ$270 million ($165 million to $171 million).

Its previous forecast was NZ$255 million to NZ$265 million.

They’ve seen better-than-expected sales in their Homecare product group combined with continued strong growth in the Hospital product group.

This includes an increase in demand from China related to the coronavirus outbreak.

Shares in Fisher & Paykel Healthcare (ASX:FPH) closed -0.04 per cent lower at $23.93 yesterday.

Copyright 2020 – Finance News Network

Source: Finance News Network

Related Posts

07JanJanuary 7, 2021

Mayne Pharma (ASX:MYX) rolls out new contraceptive pill in the US

07 Jan 2021 - Pharmaceutical giant, Mayne Pharma (ASX:MYX) has launched a new contraceptive tablet in the US.

13JunJune 13, 2023

Stocks of the Hour: Altech Batteries, Azure Minerals, Tesserent

13 Jun 2023 - A snapshot of the stocks on the move featuring Altech Batteries (ASX:ATC), Azure Minerals (ASX:AZS) and Tesserent (ASX:TNT).

09MarMarch 9, 2020

Redbubble (ASX:RBL) release interim CEO’s terms

09 Mar 2020 - Redbubble (ASX:RBL) have appointed Martin Hosking as interim CEO following Barry’s Newstead’s departure on 18 February 2020.

09JulJuly 9, 2020

Netwealth (ASX:NWL) grows FUA by 35%

09 Jul 2020 - Netwealth (ASX:NWL) grew its funds under management (FUA) by 35 per cent over the 2020 financial year, an increase of $8.2 billion to $31.5 billion.

19NovNovember 19, 2020

Immutep Limited (ASX:IMM) completes $29.6m placement to expand clinical development

19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and a new Phase II trial.

07SepSeptember 7, 2023

Stocks of the Hour: Lithium Plus Minerals, Blaze Minerals, Elsight

07 Sep 2023 - A snapshot of the stocks on the move, featuring Lithium Plus Minerals (ASX:LPM), Blaze Minerals (ASX:BLZ) and Elsight (ASX:ELS).

12AprApril 12, 2022

Broker moves: Woodside Petroleum, ANZ Bank, Nearmap

14 Apr 2022 - A snapshot of the stocks on the move featuring, Woodside Petroleum (ASX:WPL), ANZ Bank (ASX:ANZ), and Nearmap (ASX:NEA).

20AprApril 20, 2021

Afterpay (ASX:APT) sets sights on Wall Street listing

20 Apr 2021 - Buy now pay later specialist Afterpay (ASX:APT) has expressed an interest in listing on Wall Street, in light of its shareholder base expanding globally and beyond domestic stock investors.

17JulJuly 17, 2023

Stocks of the Hour: Calmer Co Intl, DroneShield, Sovereign Metals

17 Jul 2023 - A snapshot of the stocks on the move, featuring Calmer Co. International (ASX:CCO), DroneShield (ASX:DRO) and Sovereign Metals (ASX:SVM).

11SepSeptember 11, 2019

Tabcorp advised by the AFP that it has closed the Cambodia matter

11 Sep 2019 - Tabcorp (ASX:TAH) has been advised today by the Australian Federal Police that it has closed its investigation into the Cambodian matter.